Skip to content
Zenas BioPharma, Inc. (ZBIO) Reports a Net Loss for Q4 FY25
5 hours ago
Dollar Tree, Inc. (DLTR) Beats Q4 Earnings Estimates
6 hours ago
CytomX Therapeutics, Inc. (CTMX) Reports Net Loss for FY25
6 hours ago
VNET Group, Inc. (VNET) Q4 2025 Revenue Rises 19.6%
7 hours ago
VinFast Auto Ltd. (VFS) Reports a Wider Loss for Q4 FY25
7 hours ago
Townsquare Media, Inc. (TSQ) Beats Q4 EPS Estimates
7 hours ago
Science Applications International (SAIC) Beats Q4 EPS Estimates
7 hours ago
Bitcoin Depot Inc. (BTM) Reports Q4 Earnings
7 hours ago
NXP Semiconductors (NXPI) Maintains $1.01 Quarterly Dividend, 2.13% Yield With March 25 Ex-Date
9 hours ago
Methanex (MEOH) Stock Plunges 10.9% as Q4 Loss of $0.14/Share Misses Estimate by 121.7%
10 hours ago
Zenas BioPharma, Inc. (ZBIO) Reports a Net Loss for Q4 FY25
5 hours ago
Dollar Tree, Inc. (DLTR) Beats Q4 Earnings Estimates
6 hours ago
CytomX Therapeutics, Inc. (CTMX) Reports Net Loss for FY25
6 hours ago
VNET Group, Inc. (VNET) Q4 2025 Revenue Rises 19.6%
7 hours ago
VinFast Auto Ltd. (VFS) Reports a Wider Loss for Q4 FY25
7 hours ago
Townsquare Media, Inc. (TSQ) Beats Q4 EPS Estimates
7 hours ago
Science Applications International (SAIC) Beats Q4 EPS Estimates
7 hours ago
Bitcoin Depot Inc. (BTM) Reports Q4 Earnings
7 hours ago
NXP Semiconductors (NXPI) Maintains $1.01 Quarterly Dividend, 2.13% Yield With March 25 Ex-Date
9 hours ago
Methanex (MEOH) Stock Plunges 10.9% as Q4 Loss of $0.14/Share Misses Estimate by 121.7%
10 hours ago
- Fourth-quarter revenues declined to $2.51 million from $31.0 million in the corresponding quarter last year
- The company reported a net loss of $41.2 million for Q4, compared to a loss $23.5 million a year earlier
- On a per-share basis, the fourth-quarter loss widened to $0.55 from $0.31 in the year-ago quarter
- As of December 31, 2025, the company had $270.6 million in cash, cash equivalents, and marketable securities
- Other income was $2.7 million in Q4, compared to $4.4 million in the prior-year period
- Q4 G&A expenses decreased to $15.4 million from $16.2 million in the fourth quarter of last year
- R&D expenses were $31.2 million in 4Q 2025, versus $37.1 million in the comparable period of 2024
- This month, Zymeworks entered into a $250.0 million royalty-backed note financing arrangement with Royalty Pharma
